1.1.1.49 glucose-6-phosphate dehydrogenase (NADP+) artery G6PD is more than 2fold higher in pulmonary arteries compared with coronary arteries 697523 1.11.1.12 phospholipid-hydroperoxide glutathione peroxidase artery smooth muscle cells 688464 1.13.11.33 arachidonate 15-lipoxygenase artery - -, 742845 1.13.11.52 indoleamine 2,3-dioxygenase artery - 726042 1.14.14.18 heme oxygenase (biliverdin-producing) artery pulmonary 684348 1.15.1.1 superoxide dismutase artery internal mammary arteries 675625 1.17.3.2 xanthine oxidase artery - 684354 1.17.4.4 vitamin-K-epoxide reductase (warfarin-sensitive) artery mainly in vascular endothelium 675907 1.2.1.3 aldehyde dehydrogenase (NAD+) artery - 697280 1.2.1.47 4-trimethylammoniobutyraldehyde dehydrogenase artery - 743576 1.4.3.13 protein-lysine 6-oxidase artery highly expressed in vascular lesions 684889 1.6.1.2 NAD(P)+ transhydrogenase (Re/Si-specific) artery - 392595 1.6.3.1 NAD(P)H oxidase (H2O2-forming) artery - 685976, 710782 1.6.3.1 NAD(P)H oxidase (H2O2-forming) artery coronary artery endothelial cells 687649 1.6.3.1 NAD(P)H oxidase (H2O2-forming) artery human pulmonary artery endothelial cell, induction of NAD(P)H oxidase by exposure to hyperoxia for 3 h. Pretreatment of cells with the actin-stabilizing agent phallacidin attenuates hyperoxia-induced cortical actin thickening and reactive oxygen species production, whereas cytochalasin D and latrunculin A enhance basal and hyperoxia-induced reactive oxygen species formation. A 3-h hyperoxic exposure enhances the tyrosine phosphorylation of cortactin and interaction between cortactin and subunit p47phox. Transfection of cells with cortactin small interfering RNA or myristoylated cortactin Src homology domain 3 blocking peptide attenuated reactive oxygen species production and the hyperoxia-induced translocation of p47phox to the cell periphery 687587 1.6.3.1 NAD(P)H oxidase (H2O2-forming) artery in the mesenteric arteries of streptozotocin-induced diabetic apoE-deficient mice the expression of nox4 and gp91phox, ie. nox2 subunits of NADPH oxidase are enhanced as are endothelial nitric oxide synthase mRNA and protein 686552 1.6.3.1 NAD(P)H oxidase (H2O2-forming) artery porcine coronary artery endothelial cell, PCAEC. Exposure of cells to hypoxia for 2 h followed by 1 h of reoxygenation significantly increases reactive oxygen species formation. Pretreatment with the NADPH oxidase inhibitors, diphenyleneiodonium and apocynin , significantly attenuates hypoxia/reoxygenation-induced reactive oxygen species formation. Exposure of PCAECs to hypoxia/reoxygenation causes a significant increase in serine-threonine kinase Akt and ERK1/2 activation. Exposure of PCAEC spheroids to hypoxia/reoxygenation significantly increases endothelial spheroid sprouting, whereas pharmacological inhibition of NADPH oxidase or genetic deletion of the NADPH oxidase subunit, p47phox (p47phox/), significantly suppresses these changes 684345 1.6.3.1 NAD(P)H oxidase (H2O2-forming) artery smoking impaires acetylcholine-induced relaxations of carotid arteries, which can be improved by the NAD(P)H oxidase inhibitor apocynin. Both smoking and in vitro cigarette smoke extract exposure significantly increase vascular superoxide anion production 684343 1.6.3.1 NAD(P)H oxidase (H2O2-forming) artery study on enzyme activity, function, and expression in cerebral and systemic arteries. Superoxide production from enzyme is 10- to 100fold greater in intracranial arteries, basilar and middle cerebral arteries than in aorta, carotid, renal or mesenteric arteries. Isoform Nox4 shows 10fold higher expression in the basilar arteries versus aorta, carotid and mesenteric arteries 673106 1.6.5.2 NAD(P)H dehydrogenase (quinone) artery pulmonary arterial endothelial cell. Increase in enzyme protein and activity upon hyperoxia, i.e. exposure to 95% O2 for 48 h 671220 2.1.1.72 site-specific DNA-methyltransferase (adenine-specific) artery intercranial artery 719373 2.2.1.2 transaldolase artery wall 486027 2.3.1.149 Platelet-activating factor acetyltransferase artery detected by immunohistochemistry in the media of mammary arteries 693520 2.3.1.26 sterol O-acyltransferase artery - 486677 2.3.1.B41 protein-long-chain fatty-acyl-lysine deacylase (NAD+) artery - 756672 2.4.1.224 glucuronosyl-N-acetylglucosaminyl-proteoglycan 4-alpha-N-acetylglucosaminyltransferase artery - 736318 2.4.1.225 N-acetylglucosaminyl-proteoglycan 4-beta-glucuronosyltransferase artery - 736318 2.4.3.9 lactosylceramide alpha-2,3-sialyltransferase artery in atherosclerosis, excessive GM3 is synthesized in atherosclerotic lesions by macrophages and dendritic cells directly within the arterial walls in blood arteries additionally to the GM3 synthesis in blood plasma, the fatty acid compositions of GM3 from blood plasma low density lipoprotein and from atherosclerotic lesions differ 657703 2.4.3.9 lactosylceramide alpha-2,3-sialyltransferase artery level of GM3 synthase in membrane-fractions isolated from the atherosclerotic intima are higher compared to those in non-dieased arterial tissue 657703 2.7.1.137 phosphatidylinositol 3-kinase artery - 708145, 708681 2.7.1.153 phosphatidylinositol-4,5-bisphosphate 3-kinase artery - 708686 2.7.1.91 sphingosine kinase artery gracilis muscle resistance artery. Pressure-dependent activation and translocation of isoform Sk1 by ERK1/2 is critically dependent on its serine225 phosphorylation site 701973 2.7.11.10 IkappaB kinase artery mesenteric artery 761776 2.7.11.12 cGMP-dependent protein kinase artery - 662462, 702471 2.7.11.13 protein kinase C artery - 671952 2.7.11.13 protein kinase C artery coronary 660673 2.7.11.13 protein kinase C artery pulmonary 660666 2.7.11.15 beta-adrenergic-receptor kinase artery - 684355 2.7.11.17 Ca2+/calmodulin-dependent protein kinase artery - 722742 2.7.11.18 myosin-light-chain kinase artery - 709692 2.7.11.18 myosin-light-chain kinase artery maximal stimulation-induced in situ myosin light chain kinase activity is upregulated in fetal compared to adult ovine carotid arteries 684356 2.7.11.18 myosin-light-chain kinase artery small resistance mesenteric artery -, 740289 2.7.11.30 receptor protein serine/threonine kinase artery - 705441 2.7.11.31 [hydroxymethylglutaryl-CoA reductase (NADPH)] kinase artery intrapulmonary smooth muscle 692195 2.7.8.1 ethanolaminephosphotransferase artery CEPT1 is elevated in diseased lower extremity arterial intima of individuals with peripheral arterial disease and diabetes 760955 2.7.8.2 diacylglycerol cholinephosphotransferase artery CEPT1 is elevated in diseased lower extremity arterial intima of individuals with peripheral arterial disease and diabetes 760955 2.8.2.1 aryl sulfotransferase artery pulmonary, endothelial cell 677196 2.8.2.17 chondroitin 6-sulfotransferase artery - 645752 2.8.2.33 N-acetylgalactosamine 4-sulfate 6-O-sulfotransferase artery - 674051 2.8.2.8 [heparan sulfate]-glucosamine N-sulfotransferase artery - 645926 3.1.1.47 1-alkyl-2-acetylglycerophosphocholine esterase artery nonatherogenic mammary artery 693520 3.1.26.10 ribonuclease IX artery - 646297 3.1.3.53 [myosin-light-chain] phosphatase artery - 699755, 749533 3.1.3.53 [myosin-light-chain] phosphatase artery coronary artery smooth muscle 666160 3.1.3.53 [myosin-light-chain] phosphatase artery first-order mesenteric resistance artery, high expression of enzyme with predominance of 3’-exon-excluded, leucine-zipper negative MYPT 1 isoform 663585 3.1.3.53 [myosin-light-chain] phosphatase artery iliac artery, expression of leucine-zipper positive isoform of MYPT 1 predominates in healthy animal 664610 3.1.3.53 [myosin-light-chain] phosphatase artery intrapulmonary arterial tissue, enzyme protein increases with age and is highest in adult rat. In contrast, enzyme specific activity is significantly higher in fetal compared with adult tissue 663593 3.1.3.53 [myosin-light-chain] phosphatase artery monolayers of pulmonary artery endothelial cells 665653 3.1.3.53 [myosin-light-chain] phosphatase artery of tail 664611 3.1.3.53 [myosin-light-chain] phosphatase artery pulmonary artery, predominantly expression of 3’-exon-out/leucine-zipper positive MYPT 1 isoform 663585 3.1.4.11 phosphoinositide phospholipase C artery mesenteric, pulmonary and middle cerebral arteries 751920 3.1.4.17 3',5'-cyclic-nucleotide phosphodiesterase artery PDE 1 vascular expression is increased in arteries from angiotensin II hypertensive rats -, 715153 3.1.4.3 phospholipase C artery intrapulmonary arteries 731015 3.1.4.35 3',5'-cyclic-GMP phosphodiesterase artery in the vasculature, PDE5 is the predominant PDE isoform involved in degrading cGMP 711925 3.1.4.35 3',5'-cyclic-GMP phosphodiesterase artery PDE5 vascular expression is decreased in arteries from angiotensin II hypertensive rats compared to control rats -, 715153 3.3.2.10 soluble epoxide hydrolase artery - 707303, 707309 3.3.2.10 soluble epoxide hydrolase artery renal, in the smooth muscle layer of the arterial wall 660664 3.4.11.2 membrane alanyl aminopeptidase artery arterial smooth muscle 683811 3.4.14.5 dipeptidyl-peptidase IV artery in artery DPIV represents 92% of the total Gly-L-Pro-4-nitroanilide-hydrolyzing activity 697386 3.4.15.1 peptidyl-dipeptidase A artery - -, 709411, 752444 3.4.17.15 carboxypeptidase A2 artery mesenteric arterial bed, enzyme is identical with its pancreatic counterpart 732609 3.4.17.23 angiotensin-converting enzyme 2 artery non-diseased mammary arteries and atherosclerotic carotid arteries. Total vessel wall expression of ACE and ACE2 is similar during all stages of atherosclerosis. The observed ACE2 protein is enzymatically active and activity is lower in the stable advanced atherosclerotic lesions, compared to early and ruptured atherosclerotic lesions 693806 3.4.21.37 leukocyte elastase artery pulmonary artery endothelial cells 707071 3.4.21.39 chymase artery gastroepiploic 81374, 81375 3.4.21.39 chymase artery gastroepiploic artery 679291 3.4.21.46 complement factor D artery PDGF-D is widely expressed in most neointimas in arteries exhibiting the chronic arteriopathy of chronic allograft nephropathy and is only weakly expressed in a small proportion of sclerotic arteries. The neointimal cells expressing PDGF-D are alpha-smooth muscle actin-expressing cells, but not infiltrating macrophages or endothelial cells 698194 3.4.21.6 coagulation factor Xa artery middle cerebral 651191 3.4.21.7 plasmin artery vessel wall 717165 3.4.21.B1 hyaluronan-binding serine protease artery abundant in neointima and in arteriosclerotic carotid arteries, but not in normal arteries. Accumulation in unstable coronary atherosclerotic plaques with elevated RNA expression in patients with acute coronary syndromes 687108 3.4.21.B1 hyaluronan-binding serine protease artery FSAP expression in stable and especially unstable coronary atherosclerotic lesions. FSAP mainly in inflammatory regions within the shoulders of the plaque surounding or located within the lipid core that is infiltrated by macrophages. Some FSAP present within fibrotic regions in the cap of the plaque. Tight colocalization of FSAP and uPA-presenting cells in all plaques. Colocalization also with CD11b/CD68. Also present in hypocellular- and lipid rich areas of atherosclerotic plaques in internal mammary arteries, absent from normal non-atherosclerotic arteries 684801 3.4.21.B26 proprotein convertase 5 artery - 675490 3.4.22.1 cathepsin B artery cerebral arterial walls 701244 3.4.22.B60 cathepsin L2 artery - -, 753117 3.4.24.24 gelatinase A artery aged arterial wall, colocalization of activated enzyme and transforming growth factor TGF-beta1. Treatment of young aortic rings with activated enzyme enhances active transforming growth factor TGF-beta-1, collagen, and fibronectin expression to the level of untreated old counterparts 667356 3.4.24.35 gelatinase B artery - 695947 3.4.24.79 pappalysin-1 artery - 683504 3.4.24.79 pappalysin-1 artery coronary 683969 3.4.24.86 ADAM 17 endopeptidase artery atherosclerotic plaque 677450 3.4.24.B9 ADAM9 endopeptidase artery carotid and femoral arteries, only weak ADAM-9 expression from thyroid artery without atherosclerosis 710868 4.2.1.3 aconitate hydratase artery coronary artery endothelial cells 747827 4.4.1.1 cystathionine gamma-lyase artery - 690376, 691828, 693818 4.4.1.1 cystathionine gamma-lyase artery tail 707582 4.6.1.2 guanylate cyclase artery - 691656 4.6.1.2 guanylate cyclase artery coronary artery 748700 4.6.1.2 guanylate cyclase artery isozymes GC-A 692548 4.6.1.2 guanylate cyclase artery pulmonary 684348, 691656, 692204 4.6.1.2 guanylate cyclase artery pulmonary, but not aorta 691541 4.6.1.2 guanylate cyclase artery pulmonary, cultured model 690369 5.3.1.8 mannose-6-phosphate isomerase artery - 2624 5.3.99.4 prostaglandin-I synthase artery - 748544 5.3.99.4 prostaglandin-I synthase artery exposure of isolated coronary arteries to high glucose switches angiotensin II-stimulated prostacyclin-dependent relaxation into a persitent vascoconstriction. High glucose, but not mannitol, significantly increases superoxide and nitration of tyrosine in prostacyclin synthase. Concurrent administration of polyethylene-coated superoxide dismutase, L-nitroarginine methyl ester, or sepiapterin abolishes enzyme nitration, as well as its association with endothelial nitric oxide synthase 679435 5.3.99.4 prostaglandin-I synthase artery vascular 37464